RxDoctor Payments Data

Habtamu Handro, MD

Internal Medicine · Lansing, MINPI 1558316000

Payments from drug & device makers

$5,510in general payments, 2019–2025

Across 337 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$904
  • Lilly USA, LLC$643
  • Pfizer$476
  • Novartis$408
  • Astellas Pharma US Inc$285
  • Boehringer Ingelheim$267
  • plus $3K from 51 others

What the payments were for

  • Food & beverage$5,12893%
  • Education$1913%
  • Other$1923%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,510 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$52,920
Medicare patients
284
Services billed
574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide231$300,737
JardianceEmpagliflozin136$175,357
OzempicSemaglutide103$175,150
SynjardyEmpagliflozin/Metformin Hcl91$133,050
EliquisApixaban95$121,421
JanuviaSitagliptin Phosphate76$107,617
TrulicityDulaglutide53$87,993
JanumetSitagliptin Phos/Metformin Hcl53$75,966
FarxigaDapagliflozin Propanediol61$73,685
RybelsusSemaglutide21$42,511
XareltoRivaroxaban26$40,946
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$27,348
TradjentaLinagliptin21$26,558
WegovySemaglutide17$26,072
MyrbetriqMirabegron28$25,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$643$388,730284 claims
Boehringer IngelheimJardiance, Synjardy, Tradjenta$267$334,965248 claims
Novo NordiskOzempic, Rybelsus, Wegovy$904$243,733141 claims
MerckJanuvia, Janumet$261$183,583129 claims
PfizerEliquis, Nurtec Odt$476$143,152107 claims
AstraZenecaFarxiga, Symbicort$72$78,19776 claims
Johnson & JohnsonXarelto$164$40,94626 claims
GSKTrelegy Ellipta$121$27,34830 claims
Astellas Pharma US IncMyrbetriq$285$25,56228 claims
AmgenProlia$201$25,55115 claims
NovartisEntresto$408$18,40221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →